LEXINGTON, Ky.--(BUSINESS WIRE)-- Orthopeutics, LP, the parent company of Intralink Spine, Inc., Intrabrace, LLC, Tarexx, LLC, and Equinext, LLC, will soon be awarded its 7th US patent covering NEXTTM, a novel injectable treatment to repair degraded and painful spinal discs and other highly prevalent soft tissue disorders. The latest patent, US 8,283,322, addresses reagent formulations for their injectable tissue-repair products. Other US patents held by Orthopeutics cover treatments for spinal disc degradation, spinal deformity (scoliosis, kyphosis, and spondylolisthesis), tearing of the disc or knee meniscus, nutritional deficiencies that impede stem cell and cytokine therapies, and preventing expulsion of implanted devices or materials. Several international patents have also been issued and several more US and international patents are pending.
“Our initial goal was to develop an effective, immediate, and permanent solution for back pain that would also dramatically reduce health care costs,” says Tom Hedman, Ph.D., inventor and current President of Orthopeutics. “A decade of testing has convinced us that NEXT will provide superior effectiveness in a number of applications at a fraction of the cost of surgical approaches. With the ever-escalating costs for healthcare, this treatment platform would be a big step in the right direction.”
Orthopeutics has commenced the human clinical trials phase of NEXT for degenerative disc disease, engaging multiple clinical specialties to validate their custom injection-delivery protocol, with overseas first-in-man trials around the corner. At the same time, Equinext, a Lexington based company that Orthopeutics launched in 2011, is on pace to initiate US sales of its product to treat tendon and ligament lesions in horses in the first half of 2013.
Orthopeutics is a privately held technology incubator focused on providing low-cost but superior injectable solutions for soft-tissue repair. Orthopeutics was spun out of the University of Southern California in 2004, and is currently affiliated with the University of Kentucky. To discuss investment, licensing or acquisition opportunities, please contact Dr. Hedman at email@example.com, 512-818-8468, www.orthopeutics.com.
Dr. Tom Hedman, 512-818-8468
Source: Orthopeutics, LP